SCH 727965 in Patients With Advanced Breast and Lung Cancers (Study P04716)
- Conditions
- Carcinoma, Non-Small-Cell LungBreast Neoplasms
- Interventions
- Registration Number
- NCT00732810
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Brief Summary
To determine the activity of SCH 727965 in participants with breast cancer and in participants with nonsmall-cell lung cancer (NSCLC) compared to standard treatment. The standard treatment used is capecitabine for breast cancer and erlotinib for NSCLC. The study will also determine the activity of SCH 727965 treatment in participants who experience cancer progression after standard treatment.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 97
-
Age >=18 years, either sex, any race.
-
Histologically or cytologically confirmed breast cancer or NSCLC; and radiographic or clinically advanced disease.
-
BREAST CANCER:
- participant must have previously received both a taxane and an anthracycline (unless anthracycline therapy is contraindicated) in the adjuvant and/or metastatic setting,
- participant with HER2-positive disease must have progressed after trastuzumab and concomitant or subsequent lapatinib,
- participant must have received at least one, but no more than two prior regimens for recurrent or metastatic disease (endocrine and biologic therapies do not count as chemotherapeutic regimens).
-
NSCLC: at least one, but no more than two prior chemotherapeutic regimens for advanced disease.
-
Measurable disease by the RECIST.
-
Eastern Cooperative Oncology Group performance status of 0, 1, or 2.
-
Adequate hematologic, renal, and hepatic organ function and laboratory parameters.
-
Ability to swallow tablets.
-
Known brain metastases. For NSCLC only, a participant with central nervous system metastasis is eligible provided the participant has received definitive local therapy (ie, radiation therapy or surgery), has stopped receiving treatment with corticosteroids, and is without symptoms for at least 4 weeks before randomization.
-
History of previous radiation therapy to >25% of total bone marrow.
-
Known HIV infection.
-
Known active hepatitis B or hepatitis C.
-
Previous treatment with SCH 727965 or other cyclin-dependent-kinase inhibitors.
-
BREAST CANCER:
- known dihydropyrimidine dehydrogenase deficiency,
- previous treatment with capecitabine.
-
NSCLC: previous treatment with erlotinib.
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- PARALLEL
- Arm && Interventions
Group Intervention Description NSCLC randomized to erlotinib Erlotinib Note: Enrollment of participants with NSCLC was completed per protocol as of 26 JAN 2010 NSCLC randomized to SCH 727965 SCH 727965 Note: Enrollment of participants with NSCLC was completed per protocol as of 26 JAN 2010 SCH 727965 in NSCLC after progression on erlotinib SCH 727965 Note: Crossover to SCH 727965 after progression on erlotinib was completed per protocol as of 26 JAN 2010 Breast cancer randomized to SCH 727965 SCH 727965 - SCH 727965 in breast cancer after progression on capecitabine SCH 727965 - Breast cancer randomized to capecitabine Capecitabine -
- Primary Outcome Measures
Name Time Method Time to disease progression. Every 6 weeks for 30 weeks, and then every 9 weeks. Assessments continue until disease progression. Date of randomization to date of tumor progression.
Overall response rate in participants treated with SCH 727965 after disease progression on the comparator drug. Every 6 weeks for 30 weeks, and then every 9 weeks. Percentage of participants with tumor responses (partial responses + complete responses).
- Secondary Outcome Measures
Name Time Method